Temporal dynamics of cortical and subcortical responses to apomorphine in Parkinson disease: An H215O PET study

Clinical Neuropharmacology

Volumn 28, Issue 1, 2005, Pages 18-27

  Hosey, Lara A ^a   Thompson, Jennifer L W ^a   Verhagen Metman, Leonard ^b   Van Den Munckhof, Pepyn ^c   Braun, Allen R ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Apomorphine; Dopamine agonists; Parkinson disease; Pharmacodynamics

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYNAMICS; FEMALE; HUMAN; LIMBIC CORTEX; MALE; PARIETAL LOBE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SENSORIMOTOR CORTEX; THALAMOCORTICAL TRACT; THALAMUS VENTRAL NUCLEUS;

ADULT; AGED; APOMORPHINE; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN RADIOISOTOPES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 13944283025     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000154220.30263.0e     Document Type: Article

References (43)

1. Wichmann T, DeLong MR. Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am. 1998;9:223-236.
2. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:117-164.
3. Scarselli M, Armogida M, Pardini C, et al. Apomorphine. A novel effect for an old compound. Adv Neurol. 2001;86:367-372.
4. Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53:1004-1007.
5. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
6. 15O]water studies with short interscan interval for single-subject and group analysis: influence of background subtraction. J Cereb Blood Flow Metab. 1998;18:433-443.
7. Horwitz B, McIntosh A. Quantification of Brain Function. Amsterdam: Excerpta Medica, 1994, 589-596.
8. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 1993;43(12 Suppl 6):S6-S16.
9. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783-801.
10. Wolfson LI, Leenders KL, Brown LL, et al. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology. 1985;35:1399-1405.
11. 14C]2-deoxy-D- glucose incorporation into neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res. 1980;197:167-183.
12. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord. 2001;16:1014-1022.
13. Inase M, Sakai ST, Tanji J. Overlapping corticostriatal projections from the supplementary motor area and the primary motor cortex in the macaque monkey: an anterograde double labeling study. J Comp Neurol. 1996;373:283-296.
14. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol. 1992;32:749-757.
15. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurologic. 2001;57:2083-2088.
16. Grasby PM, Fristen KJ, Bench CJ, et al. The effect of the dopamine agonist, apomorphine, on regional cerebral blood flow in normal volunteers. Psychol Med. 1993;23:605-612.
17. 2O PET study in humans. Neurosci Lett. 1994;176:21-24.
18. Hershey T, Black KJ, Stambuk MK, et al. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA. 1998;95:12016-12021.
19. Fog R. Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs. Psychopharmacologia. 1969;14:299-304.
20. Strombom U. Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1976;292:167-176.
21. Kellett MW, Steiger MJ. Deterioration in parkinsonism with low-dose pergolide. J Neurol. 1999;246:309-311.
22. Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism. Psychopharmacologia. 1976;47:169-173.
23. Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26:232-238.
24. Castaigne P, Laplane D, Dordain G. Clinical experimentation with apomorphine in Parkinson's disease. Res Commun Chem Pathol Pharmacol. 1971;2:154-158.
25. Marsh GG, Markham CM, Ansel R. Levodopa's awakening effect on patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971;34: 209-218.
26. Girotti F, Carella F, Grassi MP, et al. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry. 1986;49:657-660.
27. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain. 1988; 111:299-321.
28. Coenen AM. Neuronal phenomena associated with vigilance and consciousness: from cellular mechanisms to electroencephalographic patterns. Conscious Cogn. 1998;7:42-53.
29. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev. 1983; 63:844-914.
30. Fetoni V, Soliveri P, Monza D, et al. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry. 1999;66:541-544.
31. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med. 1987; 17:899-904.
32. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628-3641.
33. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158: 899-905.
34. Lange KW, Robbins TW, Marsden CD, et al. L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl). 1992; 107:394-404.
35. Cabeza R, Nyberg L. Imaging cognition II: An empirical review of 275 PET and fMR1 studies. J Cogn Neurosci. 2000;12:1-47.
36. Frith CD, Friston K, Liddle PF, et al. Willed action and the prefrontal cortex in man: a study with PET. Proc R Soc Lond B Biol Sci. 1991; 244:241-246.
37. Locatelli E, Verhagen-Metman L, Blin J. Levodopa- or apomorphine-induced motor improvements in Parkinson's disease (PD) associated with decreased neuronal activity in basal ganglia. Neurology. 1995;45: A251.
38. Thach WT, Goodkin HP, Keating JG. The cerebellum and the adaptive coordination of movement. Annu Rev Neurosci. 1992;15:403-442.
39. Groenewegen HJ, Berendse HW. The specificity of the " nonspecific" midline and intralaminar thalamic nuclei. Trends Neurosci. 1994;17: 52-57.
40. Jones EG, Leavitt RY. Retrograde axonal transport and the demonstration of non-specific projections to the cerebral cortex and striatum from thalamic intralaminar nuclei in the rat, cat and monkey. J Comp Neurol. 1974;154:349-377.
41. Cooke JD, Brown JD, Brooks VB. Increased dependence on visual information for movement control in patients with Parkinson's disease. Can J Neurol Sci. 1978;5:413-415.
42. Giladi N, McMahon D, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology. 1992;42:333-339.
43. Azulay JP, Mesure S, Amblard B, et al. Visual control of locomotion in Parkinson's disease. Brain. 1999;122:111-120.